These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 22563174)

  • 1. Is hepatic arterial infusion chemotherapy effective treatment for advanced hepatocellular carcinoma resistant to transarterial chemoembolization?
    Kirikoshi H; Yoneda M; Mawatari H; Fujita K; Imajo K; Kato S; Suzuki K; Kobayashi N; Kubota K; Maeda S; Nakajima A; Saito S
    World J Gastroenterol; 2012 Apr; 18(16):1933-9. PubMed ID: 22563174
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparative study of high-dose hepatic arterial infusion chemotherapy and transarterial chemoembolization using doxorubicin for intractable, advanced hepatocellular carcinoma.
    Kim HY; Kim JD; Bae SH; Park JY; Han KH; Woo HY; Choi JY; Yoon SK; Jang BK; Hwang JS; Kim SG; Kim YS; Seo YS; Yim HJ; Um SH;
    Korean J Hepatol; 2010 Dec; 16(4):355-61. PubMed ID: 21415578
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatic artery infusion chemotherapy using mFOLFOX versus transarterial chemoembolization for massive unresectable hepatocellular carcinoma: a prospective non-randomized study.
    He MK; Le Y; Li QJ; Yu ZS; Li SH; Wei W; Guo RP; Shi M
    Chin J Cancer; 2017 Oct; 36(1):83. PubMed ID: 29061175
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin Versus Transarterial Chemoembolization for Large Hepatocellular Carcinoma: A Randomized Phase III Trial.
    Li QJ; He MK; Chen HW; Fang WQ; Zhou YM; Xu L; Wei W; Zhang YJ; Guo Y; Guo RP; Chen MS; Shi M
    J Clin Oncol; 2022 Jan; 40(2):150-160. PubMed ID: 34648352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatic Arterial Infusion Chemotherapy Using Oxaliplatin Plus 5-Fluorouracil Versus Transarterial Chemoembolization/Embolization for the Treatment of Advanced Hepatocellular Carcinoma with Major Portal Vein Tumor Thrombosis.
    Hu J; Bao Q; Cao G; Zhu X; Yang R; Ji X; Xu L; Zheng K; Li W; Xing B; Wang X
    Cardiovasc Intervent Radiol; 2020 Jul; 43(7):996-1005. PubMed ID: 31974744
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oxaliplatin and 5-fluorouracil hepatic infusion with lipiodolized chemoembolization in large hepatocellular carcinoma.
    Li JH; Xie XY; Zhang L; Le F; Ge NL; Li LX; Gan YH; Chen Y; Zhang JB; Xue TC; Chen RX; Xia JL; Zhang BH; Ye SL; Wang YH; Ren ZG
    World J Gastroenterol; 2015 Apr; 21(13):3970-7. PubMed ID: 25852283
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of Outcome of Hepatic Arterial Infusion Chemotherapy and Sorafenib in Patients with Hepatocellular Carcinoma Refractory to Transcatheter Arterial Chemoembolization.
    Hatooka M; Kawaoka T; Aikata H; Morio K; Kobayashi T; Hiramatsu A; Imamura M; Kawakami Y; Murakami E; Waki K; Honda Y; Mori N; Takaki S; Tsuji K; Kohno H; Kohno H; Moriya T; Nonaka M; Hyogo H; Aisaka Y; Chayama K
    Anticancer Res; 2016 Jul; 36(7):3523-9. PubMed ID: 27354618
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transarterial chemoembolization with hepatic arterial infusion chemotherapy plus S-1 for hepatocellular carcinoma.
    Guo JH; Liu SX; Gao S; Kou FX; Zhang X; Wu D; Li XT; Chen H; Wang XD; Liu P; Zhang PJ; Xu HF; Cao G; Zhu LZ; Yang RJ; Zhu X
    World J Gastroenterol; 2020 Jul; 26(27):3975-3988. PubMed ID: 32774071
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemoembolization alone vs combined chemoembolization and hepatic arterial infusion chemotherapy in inoperable hepatocellular carcinoma patients.
    Gao S; Zhang PJ; Guo JH; Chen H; Xu HF; Liu P; Yang RJ; Zhu X
    World J Gastroenterol; 2015 Sep; 21(36):10443-52. PubMed ID: 26420971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atezolizumab and bevacizumab plus transarterial chemoembolization and hepatic arterial infusion chemotherapy for patients with high tumor burden unresectable hepatocellular carcinoma: A multi-center cohort study.
    Huang Z; Chen T; Li W; He W; Liu S; Wu Z; Li B; Yuan Y; Qiu J
    Int Immunopharmacol; 2024 Sep; 139():112711. PubMed ID: 39029233
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of hepatic arterial infusion chemotherapy versus sorafenib monotherapy in patients with advanced hepatocellular carcinoma.
    Kawaoka T; Aikata H; Hyogo H; Morio R; Morio K; Hatooka M; Fukuhara T; Kobayashi T; Naeshiro N; Miyaki D; Hiramatsu A; Imamura M; Kawakami Y; Takahashi S; Waki K; Tsuji K; Kohno H; Kohno H; Moriya T; Chayama K
    J Dig Dis; 2015 Sep; 16(9):505-12. PubMed ID: 26121102
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatic arterial infusion chemotherapy for patients with huge unresectable hepatocellular carcinoma.
    Tsai WL; Lai KH; Liang HL; Hsu PI; Chan HH; Chen WC; Yu HC; Tsay FW; Wang HM; Tsai HC; Cheng JS
    PLoS One; 2014; 9(5):e92784. PubMed ID: 24824520
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatic Artery Infusion Chemotherapy Using Fluorouracil, Leucovorin, and Oxaliplatin versus Transarterial Chemoembolization as Initial Treatment for Locally Advanced Hepatocellular Carcinoma: A Propensity Score-Matching Analysis.
    Li S; Lyu N; Han X; Li J; Lai J; He M; Deng H; Shi M; Wang H; Zhao M
    J Vasc Interv Radiol; 2021 Sep; 32(9):1267-1276.e1. PubMed ID: 34166806
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic factors in patients with advanced hepatocellular carcinoma receiving hepatic arterial infusion chemotherapy.
    Yamasaki T; Kimura T; Kurokawa F; Aoyama K; Ishikawa T; Tajima K; Yokoyama Y; Takami T; Omori K; Kawaguchi K; Tsuchiya M; Terai S; Sakaida I; Okita K
    J Gastroenterol; 2005 Jan; 40(1):70-8. PubMed ID: 15692792
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Effectiveness and Safety of Transarterial Chemoembolization: Hepatic Artery Infusion Chemotherapy Plus Tyrosine Kinase Inhibitors With or Without Programmed Cell Death Protein-1 Inhibitors for Unresectable Hepatocellular Carcinoma-A Retrospective Study.
    Chen Y; Jia L; Li Y; Cui W; Wang J; Zhang C; Bian C; Wang Z; Lin D; Luo T
    Ann Surg Oncol; 2024 Nov; 31(12):7860-7869. PubMed ID: 39090499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of clinical outcome of hepatic arterial infusion chemotherapy and sorafenib for advanced hepatocellular carcinoma according to macrovascular invasion and transcatheter arterial chemoembolization refractory status.
    Kodama K; Kawaoka T; Aikata H; Uchikawa S; Inagaki Y; Hatooka M; Morio K; Nakahara T; Murakami E; Tsuge M; Hiramatsu A; Imamura M; Kawakami Y; Masaki K; Honda Y; Mori N; Takaki S; Tsuji K; Kohno H; Kohno H; Moriya T; Nonaka M; Hyogo H; Aisaka Y; Chayama K
    J Gastroenterol Hepatol; 2018 Oct; 33(10):1780-1786. PubMed ID: 29645345
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial.
    Kudo M; Ueshima K; Yokosuka O; Ogasawara S; Obi S; Izumi N; Aikata H; Nagano H; Hatano E; Sasaki Y; Hino K; Kumada T; Yamamoto K; Imai Y; Iwadou S; Ogawa C; Okusaka T; Kanai F; Akazawa K; Yoshimura KI; Johnson P; Arai Y;
    Lancet Gastroenterol Hepatol; 2018 Jun; 3(6):424-432. PubMed ID: 29631810
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatic Arterial Infusion Chemotherapy with Modified FOLFOX as an Alternative Treatment Option in Advanced Hepatocellular Carcinoma Patients with Failed or Unsuitability for Transarterial Chemoembolization.
    Hsu SJ; Xu X; Chen MP; Zhao ZY; Wang Y; Yin X; Zhang L; Ge NL; Chen Y; Wang YH; Luo JF; Ren ZG; Chen RX
    Acad Radiol; 2021 Nov; 28 Suppl 1():S157-S166. PubMed ID: 33653656
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin Versus Sorafenib for Hepatocellular Carcinoma Refractory to Transarterial Chemoembolization: Retrospective Subgroup Analysis of 2 Prospective Trials.
    Huang Y; Zhang L; He M; Lai Z; Bu X; Wen D; Li Q; Xu L; Wei W; Zhang Y; Zhou Z; Chen M; Guo R; Shi M; Kan A
    Technol Cancer Res Treat; 2022; 21():15330338221117389. PubMed ID: 36529949
    [No Abstract]   [Full Text] [Related]  

  • 20. Factors affecting survival after concurrent chemoradiation therapy for advanced hepatocellular carcinoma: a retrospective study.
    Kim JK; Kim JW; Lee IJ; Joo SM; Lee KH; Cho ES; Yu JS; Jeon TJ; Kim Y; Lee JI; Lee KS
    Radiat Oncol; 2017 Aug; 12(1):133. PubMed ID: 28810886
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.